CC

Business Context and Reporting Period

The Chemours Company (CC) filed its Form 10-Q for the quarterly period ended June 30, 2026. Chemours is a global provider of performance chemicals, operating through three principal segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. The company reported a net loss for the period, driven significantly by litigation and environmental charges, partially offset by a substantial gain on the sale of assets.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Sales: Relatively flat compared to the prior year periods (down 1% for the quarter, flat for the six months). Volume decreased by 4%, offset by a 2% price increase and favorable currency movements.
• Net Loss: The net loss narrowed significantly compared to the prior year (Q2 2025 loss of $380 million; 6M 2025 loss of $385 million). This improvement was primarily driven by a $266 million gain on the sale of nine parcels of land in Kuan Yin, Taiwan, recognized in "Other income, net."
• Operating Expenses: Selling, general, and administrative (SG&A) expenses increased by 11% in the quarter and 13% for the six months. This increase was largely due to adjustments to environmental reserves and litigation costs, partially offset by lower legacy legal fees.
• Restructuring Charges: Decreased significantly to $3 million for the quarter and $16 million for the six months, down from $18 million and $51 million in the prior year periods, respectively.
• Income Taxes: The provision for income taxes increased to $273 million for the quarter and $281 million for the six months. This was primarily due to the recognition of a full valuation allowance against U.S. federal and state deferred tax assets.

Guidance, Outlook, and Risks

• Liquidity: Management believes it has sufficient liquidity to settle current liabilities through at least August 2027. The company holds $671 million in unrestricted cash and has $953 million available under its revolving credit facility.
• Debt Activity: In March 2026, the company issued $700 million of 7.875% Senior Notes due 2034. Proceeds were used to redeem $495 million of 5.375% notes due 2027 and $188 million of 5.750% notes due 2028. The company also paid down a portion of its Euro term loan.
• Legal and Environmental Contingencies:
  • PFAS Litigation: The company faces extensive litigation regarding PFAS (including PFOA and GenX). Accrued litigation liabilities totaled $658 million as of June 30, 2026. Significant settlements include a $875 million Judicial Consent Order with the State of New Jersey (Chemours share approx. $269 million NPV) and ongoing settlements in North Carolina.
  • Environmental Remediation: Total environmental remediation liabilities were $795 million. Significant accruals were recognized in Q2 2026 related to expanded off-site drinking water programs at Washington Works and Chambers Works pursuant to a 2026 Consent Decree with the EPA and WVDEP.
  • Regulatory Risks: The company faces evolving regulations regarding PFAS in the EU (REACH restriction process) and the U.S. (EPA drinking water standards), which could increase compliance costs and liabilities.
• Segment Performance:
  • Thermal & Specialized Solutions: Adjusted EBITDA increased to $213 million (Q2) and $403 million (6M), driven by higher refrigerant prices.
  • Titanium Technologies: Adjusted EBITDA was flat for the quarter ($48 million) but declined for the six months ($67 million) due to lower volumes and higher input costs.
  • Advanced Performance Materials: Adjusted EBITDA declined significantly to $26 million (Q2) and $31 million (6M) due to the exit of the SPS Capstone business and operational impacts at the Washington Works site.

Investor Verification Checklist

• Asset Sale Gain: Verify the sustainability of the $266 million gain from the Taiwan land sale and its impact on the net loss.
• Valuation Allowance: Review the rationale for the full valuation allowance against U.S. deferred tax assets and its impact on future tax provisions.
• PFAS Liability Exposure: Assess the adequacy of the $658 million accrued litigation reserve and the potential for additional costs from the New Jersey settlement and North Carolina matters.
• Environmental Accruals: Examine the $141 million increase in environmental reserves related to the 2026 Consent Decree and the long-term cash flow implications.
• Debt Refinancing: Monitor the impact of the new 2034 Notes issuance and the reduction in interest expense on future cash flows.
• Regulatory Timeline: Track the progress of the EU REACH PFAS restriction process and EPA drinking water rule challenges, as these could materially alter future costs.